六月 2026
- Home
- Celon Pharma
六月 2026的Celon Pharma市场份额分析
Celon Pharma S.A. jest zintegrowaną firmą farmaceutyczną prowadzącą zaawansowane badania naukowe i wytwarzającą nowoczesne leki. Firma prowadzi również skuteczny marketing własnych produktów. Nasze leki pomagają tysiącom pacjentów zachować lepsze i dłuższe życie.
Celon Pharma(包含公司地区分支机构)
查看更多网站流量和参与度信息- celonpharma.com
Celon Pharma收入截至 六月 2026为 15M - 25M
Celon Pharma主要域名产生的收入
3 年中Celon Pharma主要域名的收入
Celon Pharma主要域名的收入
Celon Pharma热门域名的总访问量
了解Celon Pharma市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Celon Pharma热门域名的平均访问时长
分析Celon Pharma参与度指标。
过去 3 个月的平均访问时长
子公司明细
Celon Pharma热门域名的平均页面浏览量
了解Celon Pharma如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Celon Pharma 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Mabion SA partnered with Celon Pharma Ltd on Jan 1st '26.* Mabion's collaborations with partners and clients such as Sartorius, IBMP, NovalGen, WPD Pharmaceuticals, KriSan Biotech, Celon Pharma, SyVento and Oddifact illustrate this strategic direction, covering areas including next-generation biologics, biosimilars, ADCs, rare diseases and AI-supported indication discovery.
六月 9, 2026阅读更多
新闻Celon Pharma Ltd partnered with Pharmalink Drug Store on Jun 8th '26.The Management Board of Celon Pharma S.A. (the "Company") hereby announces that on 8 June 2026 it entered into a License and Supply Agreement with Pharmalink Drug Store L.L.C. ("Pharmalink") for the commercialization of Celon Pharma's Reduzek (semaglutide products) in multi-dose pens for subcutaneous injection.
六月 8, 2026阅读更多
新闻Celon Pharma Ltd received financing of $26.6M in loan on Mar 9th '26.Further to Current Report No. 13/2025 dated August 4, 2025, regarding the agreement with the European Bank for Reconstruction and Development ("EBRD") on the principal terms and conditions of financing to be granted to Celon Pharma Slovakia s.r.o. (a wholly owned subsidiary of Celon Pharma S.A., hereinafter the "Borrower"), the Management Board of Celon Pharma S.A. (the "Issuer") hereby announces that on March 9, 2026, the parties entered into a financing agreement (the "Agreement"), pursuant to which the EBRD agreed to provide the Borrower with financing in the form of a loan of up to EUR 23 million for the implementation of a project involving the adaptation, equipping and commissioning of a manufacturing facility located in the Žilina region of Slovakia for the production of the active pharmaceutical ingredient semaglutide, a GLP-1 analogue, intended for the treatment of type 2 diabetes (to be marketed under the trade name Reduzek).
三月 9, 2026阅读更多
查看 Celon Pharma 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
